



(12) Translation of
european patent specification

(11) NO/EP 2292231 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/4965 (2006.01)
A61P 25/00 (2006.01)
C07D 241/20 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.02.29
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.10.21
(86)	European Application Nr.	09770106.4
(86)	European Filing Date	2009.06.22
(87)	The European Application's Publication Date	2011.03.09
(30)	Priority	2008.06.23, JP, 2008162638
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	Nippon Shinyaku Co., Ltd., 14, Kisshoin Nishinosho Monguchicho Minami-ku, Kyoto-shi, Kyoto 601-8550, JP-Japan
(72)	Inventor	KUWANO, Keiichi, 13-6, Hiranouemachi 1-chome, Hirano-ku, Osaka-shi, Osaka 547-0045, JP-Japan
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **THERAPEUTIC AGENT FOR SPINAL CANAL STENOSIS**

(56) References
Cited:

EP-A1- 2 246 336
WO-A1-02/088084
WO-A1-2004/032965
ASAKI ET AL: "Structure-activity relationship study on the 6-membered heteroaromatic ring system of diphenylpyrazine-type prostacyclin receptor agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 23, 2 November 2007 (2007-11-02), pages 6588-6592, XP022325942, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.09.066
HIDEKI TOYOKAWA: 'Yobu Seikicyukan Kyosakusho no shindan-Hozon-Ryoho Yobu Sekicyukan Kyosakusho no Yakubutsu Ryoho' PAIN CLINIC vol. 22, no. 10, 2001, pages 1362 - 1368
SHIN'ICHI KONNO: 'Yobu Sekicyukan Kyosaku no Hozon Ryoho' THE JAPANESE SOCIETY OF LUMBER SPINE DISORDERS vol. 10, no. 1, 2004, pages 10 - 13, XP008147019
KEISUKE GOTO ET AL.: 'Sekitsui Shikkan eno Approach Sekichukan Kyosakusho no Shindan to Chiryō' GEKKAN RIUMACHIKA vol. 29, no. 2, 2003, pages 157 - 163, XP008147007

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

5 **1.** Middel for anvendelse i behandlingen av spinal stenose, inneholdende 2-{4-[N-(5,6-difenylpyrazin-2-yl)-N-isopropyl-amino]butyloksy}eddiksyre eller 2-{4-[N-(5,6-difenylpyrazin-2-yl)-N-isopropylamino]butyloksy}-N-(metylsulfonyl)acetamid eller et farmasøytisk akseptabelt salt derav som virkestoff.

10 **2.** Midlet ifølge krav 1 for anvendelsen ifølge krav 1, hvori den spinale stenosen er cervikal spinal stenose, torakal spinal stenose, lumbal spinal stenose, diffus spinal stenose eller sakral stenose.

15 **3.** Midlet ifølge krav 1 for anvendelsen ifølge krav 1, hvori den spinale stenosen er lumbal spinal stenose.